个人中心| | 帮助
高级检索
当前位置： 首页 > 详情页

Cobimetinib (C) combined with paclitaxel (P) as a first-line treatment in patients (pts) with advanced triple-negative breast cancer (COLET study): Updated clinical and biomarker results

| 认领 | 导出 | |

文献详情

资源类型：

收录情况： ◇ 自然指数

作者：
Brufsky, A.[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15] ; Kim, S-B[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15] ; Velu, T.[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15] ; Garcia-Saenz, J. A.[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15] ; Tan-Chiu, E.[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15] ; Sohn, J. H.[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15] ; Dirix, L.[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15] ; Borms, M. V.[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15] ; Liu, M-C[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15] ; Moezi, M. M.[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15] ; Kozloff, M. F.[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15] ; Sparano, J. A.[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15] ; Xu, N.[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15] ; Wongchenko, M.[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15] ; Simmons, B.[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15] ; McNally, V.[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15] ; Miles, D.[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15] ;
机构： [1]Univ Pittsburgh, Pittsburgh, PA USA; [2]Univ Ulsan, Coll Med, Asan Med Ctr, Seoul, South Korea; [3]Chirec Canc Inst, Brussels, Belgium; [4]Hosp Clin San Carlos, Madrid, Spain; [5]Florida Canc Res Inst, Plantation, FL USA; [6]Yonsei Univ Hlth Syst, Severance Hosp, Seoul, South Korea; [7]Sint Augustinusklin, Antwerp, Belgium; [8]AZ Groeninge, Kortrijk, Belgium; [9]Koo Fdn Sun Yat Sen Canc Ctr Taipei, Taipei, Taiwan; [10]Canc Specialists North Florida, Jacksonville, FL USA; [11]Ingalls Mem Hosp, Harvey, IL USA; [12]Montefiore Med Ctr, Albert Einstein Coll Med, Bronx, NY 10467 USA; [13]Genentech Inc, San Francisco, CA 94080 USA; [14]Roche Prod Ltd, Welwyn Garden City, Herts, England; [15]Mt Vernon Canc Ctr, London, England
出处：
DOI： 10.1158/1538-7445.SABCS16-P4-22-22
ISSN：
语种：
外文
被引次数：
WOS：
中科院(CAS)分区：
出版当年[2017]版：
大类 | 1 区 医学
小类 | 1 区 肿瘤学
最新[2023]版：
大类 | 1 区 医学
小类 | 2 区 肿瘤学
第一作者：
第一作者机构： [1]Univ Pittsburgh, Pittsburgh, PA USA; [2]Univ Ulsan, Coll Med, Asan Med Ctr, Seoul, South Korea; [3]Chirec Canc Inst, Brussels, Belgium; [4]Hosp Clin San Carlos, Madrid, Spain; [5]Florida Canc Res Inst, Plantation, FL USA; [6]Yonsei Univ Hlth Syst, Severance Hosp, Seoul, South Korea; [7]Sint Augustinusklin, Antwerp, Belgium; [8]AZ Groeninge, Kortrijk, Belgium; [9]Koo Fdn Sun Yat Sen Canc Ctr Taipei, Taipei, Taiwan; [10]Canc Specialists North Florida, Jacksonville, FL USA; [11]Ingalls Mem Hosp, Harvey, IL USA; [12]Montefiore Med Ctr, Albert Einstein Coll Med, Bronx, NY 10467 USA; [13]Genentech Inc, San Francisco, CA 94080 USA; [14]Roche Prod Ltd, Welwyn Garden City, Herts, England; [15]Mt Vernon Canc Ctr, London, England
推荐引用方式(GB/T 7714)：
Brufsky A.,Kim S-B,Velu T.,et al.Cobimetinib (C) combined with paclitaxel (P) as a first-line treatment in patients (pts) with advanced triple-negative breast cancer (COLET study): Updated clinical and biomarker results[J].CANCER RESEARCH.2017,77:-.doi:10.1158/1538-7445.SABCS16-P4-22-22.
APA：
Brufsky, A.,Kim, S-B,Velu, T.,Garcia-Saenz, J. A.,Tan-Chiu, E....&Miles, D..(2017).Cobimetinib (C) combined with paclitaxel (P) as a first-line treatment in patients (pts) with advanced triple-negative breast cancer (COLET study): Updated clinical and biomarker results.CANCER RESEARCH,77,
MLA：
Brufsky, A.,et al."Cobimetinib (C) combined with paclitaxel (P) as a first-line treatment in patients (pts) with advanced triple-negative breast cancer (COLET study): Updated clinical and biomarker results".CANCER RESEARCH 77.(2017):-

资源点击量：43389 今日访问量：0 总访问量：3120 更新日期：2024-09-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持：重庆聚合科技有限公司 地址：成都市人民南路四段55号